- Other backers included Morningside, Tenmile and Brandon Capital
- This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity and accelerate the clinical development of its pipeline of radionuclide therapies
- As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell board of directors
AdvanCell, an Australian radiopharmaceutical company, has raised $112 million in Series C financing.
SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis led the round. Other backers included Morningside, Tenmile and Brandon Capital.
This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity and accelerate the clinical development of its pipeline of radionuclide therapies.
As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell board of directors.
On the funding, Beg from SV Health Investors, said in a statement, “We are delighted to support AdvanCell’s growth and play a role in its remarkable journey through leading this oversubscribed Series C. We have looked long and deep at the field of radionuclide therapies and are confident that AdvanCell stands out with a first-in-class Pb-212-PSMA program and a best-in-class manufacturing platform.”
AdvanCell was founded in June 2019.
- Other backers included Morningside, Tenmile and Brandon Capital
- This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity and accelerate the clinical development of its pipeline of radionuclide therapies
- As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell board of directors
AdvanCell, an Australian radiopharmaceutical company, has raised $112 million in Series C financing.
SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis led the round. Other backers included Morningside, Tenmile and Brandon Capital.
This investment will fuel AdvanCell’s ongoing efforts to expand its manufacturing capacity and accelerate the clinical development of its pipeline of radionuclide therapies.
As part of the financing, Jamil M. Beg from SV Health Investors, Christopher Gagliardi from Sanofi Ventures, and Bali Muralidhar from Abingworth have joined the AdvanCell board of directors.
On the funding, Beg from SV Health Investors, said in a statement, “We are delighted to support AdvanCell’s growth and play a role in its remarkable journey through leading this oversubscribed Series C. We have looked long and deep at the field of radionuclide therapies and are confident that AdvanCell stands out with a first-in-class Pb-212-PSMA program and a best-in-class manufacturing platform.”
AdvanCell was founded in June 2019.
